Search
Flibanserin
go.drugbank.com/drugs/DB04908ApprovedInvestigationalIn December of 2025 the FDA expanded the age of the indication to include postmenopausal women, a first for the FDA and sexual health in that age group. [L54893] … In February of 2018 Flibanserin was approved by Health Canada under the brand name Addyi for a similar indication as approved by the FDA.
Drospirenone
go.drugbank.com/drugs/DB01395ApprovedInvestigationalDrospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. … [A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding
Mixtures: LÍA, Lo-ZumandimineIdursulfase
go.drugbank.com/drugs/DB01271ApprovedInvestigationalIdursulfase is a purified form of human iduronate-2-sulfatase, a lysosomal enzyme. Idursulfase is produced by recombinant DNA technology in a human cell line. … Idursulfase is a 525-amino acid glycoprotein with a molecular weight of approximately 76 kilodaltons.
Synonyms: Alpha-L-iduronate sulfate sulfataseRipretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigational[L13769] It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.[L13778] … Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]
Dihydrocodeine
go.drugbank.com/drugs/DB01551ApprovedIllicitIt is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis … It was marketed in 1911.
Mixtures: Duohist DH, EndaCof DHInternational brands: DF-118 ForteTrametinib
go.drugbank.com/drugs/DB08911ApprovedInvestigational[L45583] Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with [dabrafenib], a … [A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSodium lauryl sulfate
go.drugbank.com/drugs/DB00815ApprovedSodium Lauryl Sulfate (SLS) is an anionic surfactant naturally derived from coconut and/or palm kernel oil. It usually consists of a mixture of sodium alkyl sulfates, mainly the lauryl. … It is also used in creams and pastes to properly disperse the ingredients and as research tool in protein biochemistry. SLS also has some microbicidal activity.
Mixtures: Medi Hydro DP CleanserCategories: Compounds used in a research, industrial, or household settingTyrothricin
go.drugbank.com/drugs/DB13503ApprovedWithdrawnand 40% neutral linear gramicidins (where valine-gramicidin A is often the major gramicidin present, although the mixture composition can vary) [L4019, L4021, L4022]. … do exist [L4028].
Mifamurtide
go.drugbank.com/drugs/DB13615ApprovedInvestigationalWhile about 90% of patients with newly diagnosed osteosarcoma may achieve complete remission from first-line therapies, the prognosis is still poor for patients with non-metastatic osteosarcoma with lower … Also called L-MTP-PE, mifamurtide may be a liposomal form of of the active ingredient MTP-PE, which is a synthetic, less pyrogenic, and longer-acting derivative of muramyl dipeptide (MDP).
Ropeginterferon alfa-2b
go.drugbank.com/drugs/DB15119ApprovedInvestigational[A242005] Ropeginterferon alfa-2b is a next-generation mono-pegylated type I interferon produced from proline-IFN-α-2b in _Escherichia coli_ that has high tolerability and a long half-life. … [A242015, L39170] Ropeginterferon alfa-2b has shown efficacy in PV in _in vitro_ and _in vivo_ models and clinical trials.
Categories: Interferon Type ISynonyms: PEG-P-IFN-alfa-2b, PEG-P-IFN-alpha-2b